Glaxosmithkline Inc. has agreed to pay more than 42 million Lrb Euro81 million Rrb in restitution to end claims by more than 94 States that it inflated the prices of drugs used by cancer patients and others.
Glaxosmithkline settles claim of inflating prices on cancer drugs.